nuvaxovid - Search News

News

Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Seeking Alpha · 1d

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the only non-mRNA COVID-19 vaccine with full FDA approval, offering a differentiated alternative amid growing mRNA fatigue.

Infectious Disease Advisor · 1d

FDA Approves Novavax’s COVID-19 Vaccine Nuvaxovid

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

PharmExec · 1d

FDA Grants Full Approval to Novavax’s Nuvaxovid COVID-19 Vaccine

Previously granted Emergency Use Authorization, Nuvaxovid is now available for individuals over 12 years of age.

22hon MSN

BofA Reiterates Hold Rating on Novavax (NVAX) Stock

BofA analyst Alec Stranahan reiterated a Hold rating on Novavax, Inc. (NASDAQ:NVAX) stock, setting a price target of $10. The ...

3d

FDA’s Conditions on NVAX’s COVID-19 Jab

The FDA grants full approval to Novavax's protein-based COVID-19 vaccine after nearly a two-month delay, albeit with some new ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results